Suppression of early T-cell–receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154
- 15 June 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 75 (11) , 1864-1872
- https://doi.org/10.1097/01.tp.0000065738.58742.a9
Abstract
Background. Therapeutic targeting of Janus kinase 3 (JAK3) has received particular attention, because it is associated with the common γ signaling of cytokine receptors and thus vitally influences T-cell growth and survival. Recent evidence, however, indicates a critical role for JAK3 in signaling linked to the T-cell antigen receptor. Methods. In this study we investigated whether targeting JAK3 with a rationally designed inhibitor affects early T-cell activation events. T cells were stimulated by CD3 and CD28 cross-linking, and interleukin (IL)-2 production, activation marker expression, increase of free intracellular Ca2+ concentration, activation of the extracellular-related kinase, and nuclear translocation of transcription factors were evaluated. Results. We found that JAK3 inhibitor treatment dramatically impaired T-cell–receptor (TCR)-induced IL-2 production, surface activation marker expression (CD69, CD154), and homotypic T-cell aggregation. Accordingly, mRNA production of IL-2, interferon-γ, and IL-10 was profoundly inhibited. Molecular analysis revealed that TCR-triggered phosphorylation of phospholipase C-γ1, increase in cytoplasmic Ca2+ concentration, and activation of extracellular-related kinase were markedly reduced by the JAK3 inhibitor, resulting in substantially decreased DNA binding of nuclear factor of activated T cells and alkaline phosphatase-1 and subsequent IL-2 promoter activation. Remarkably, on TCR-independent stimulation, IL-2 production, CD69 expression, and blast formation were completely insensitive to JAK3 inhibitor treatment. Conclusion. These data indicate that pharmacologic targeting of JAK3 uncouples early TCR-triggered signaling from essential downstream events, which may have important implications for the use of such compounds in T-cell–mediated disorders such as allograft rejection or graft-versus-host disease.Keywords
This publication has 23 references indexed in Scilit:
- Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation modelBlood, 2002
- Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in miceBlood, 2001
- Concomitant Inhibition of Janus Kinase 3 and Calcineurin-Dependent Signaling Pathways Synergistically Prolongs the Survival of Rat Heart AllograftsThe Journal of Immunology, 2001
- Cytokine-independent Jak3 Activation upon T Cell Receptor (TCR) Stimulation through Direct Association of Jak3 and the TCR ComplexPublished by Elsevier ,2001
- Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency.Defects of the gc‐JAK3 signaling pathway as a modelImmunological Reviews, 2000
- The Jak-STAT pathwayMolecular Immunology, 2000
- Development of Autologous, Oligoclonal, Poorly Functioning T Lymphocytes in a Patient With Autosomal Recessive Severe Combined Immunodeficiency Caused by Defects of the Jak3 Tyrosine KinaseBlood, 1998
- The role of Jak3 in lymphoid development, activation, and signalingCurrent Opinion in Immunology, 1997
- Crucial Role of Jak3 in Negative Selection of Self-reactive T CellsThe Journal of Experimental Medicine, 1997
- IL-2 promoter-driven lacZ expression as a monitoring tool for IL-2 expression in primary T cells of transgenic miceInternational Immunology, 1994